

=> fil reg  
FILE 'REGISTRY' ENTERED AT 14:05:57 ON 25 AUG 2006

=> d his

FILE 'HCAPLUS' ENTERED AT 12:42:31 ON 25 AUG 2006  
L1 1 S US20050009863/PN  
SEL RN

FILE 'REGISTRY' ENTERED AT 12:42:52 ON 25 AUG 2006  
L2 93 S E1-E93  
L3 STR  
L4 4 S L3  
L5 STR L3  
L6 50 S L5  
L7 STR L3  
L8 STR L7  
L9 50 S L8  
L10 9243 S L8 FUL  
L11 61 S L10 AND L2  
SAV L10 DAV781/A  
L12 8 S L3 SAM SUB=L10  
L13 114 S L3 FUL SUB=L10  
L14 17 S L13 AND L2

FILE 'HCAPLUS' ENTERED AT 13:24:59 ON 25 AUG 2006  
L15 5 S L13

FILE 'STNGUIDE' ENTERED AT 13:32:20 ON 25 AUG 2006


FILE 'MARPAT' ENTERED AT 13:59:24 ON 25 AUG 2006  
L16 0 S L13 SAM  
L17 7 S L13 FUL  
L18 6 S L17 NOT L15

FILE 'MEDLINE, EMBASE, BIOSIS, CAOLD' ENTERED AT 14:02:04 ON 25  
AUG 2006  
L19 0 S L13

FILE 'BEILSTEIN' ENTERED AT 14:02:46 ON 25 AUG 2006  
L20 0 S L13 FUL

=> fil hcap  
FILE 'HCAPLUS' ENTERED AT 14:06:20 ON 25 AUG 2006

=> d que l15  
L3 STR



VPA 17-1/2/5/6 U

VPA 18-16/15/14/13/12 U

NODE ATTRIBUTES:

NSPEC IS RC AT 22

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

L8 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE


L10 9243 SEA FILE=REGISTRY SSS FUL L8

L13 114 SEA FILE=REGISTRY SUB=L10 SSS FUL L3

L15 5 SEA FILE=HCAPLUS ABB=ON L13

=> fil marpat  
FILE 'MARPAT' ENTERED AT 14:06:41 ON 25 AUG 2006

=> d que 118  
L3 STR



VPA 17-1/2/5/6 U  
VPA 18-16/15/14/13/12 U


NODE ATTRIBUTES:

NSPEC IS RC AT 22  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
L8 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I  
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L10 9243 SEA FILE=REGISTRY SSS FUL L8  
L13 114 SEA FILE=REGISTRY SUB=L10 SSS FUL L3  
L15 5 SEA FILE=HCAPLUS ABB=ON L13  
L17 7 SEA FILE=MARPAT SSS FUL L3  
L18 6 SEA FILE=MARPAT ABB=ON L17 NOT L15


=> fil medline biosis embase caold  
FILE 'MEDLINE' ENTERED AT 14:07:17 ON 25 AUG 2006

FILE 'BIOSIS' ENTERED AT 14:07:17 ON 25 AUG 2006

FILE 'EMBASE' ENTERED AT 14:07:17 ON 25 AUG 2006

FILE 'CAOLD' ENTERED AT 14:07:17 ON 25 AUG 2006

=> d que 119  
L3 STR



VPA 17-1/2/5/6 U  
VPA 18-16/15/14/13/12 U


NODE ATTRIBUTES:

NSPEC IS RC AT 22  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
L8 STR



NODE ATTRIBUTES:


DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 16


STEREO ATTRIBUTES: NONE

L10 9243 SEA FILE=REGISTRY SSS FUL L8  
L13 114 SEA FILE=REGISTRY SUB=L10 SSS FUL L3  
L19 0 SEA L13=> fil beil  
FILE 'BEILSTEIN' ENTERED AT 14:07:39 ON 25 AUG 2006=> d que 120  
L3 STRVPA 17-1/2/5/6 U  
VPA 18-16/15/14/13/12 U  
NODE ATTRIBUTES:  
NSPEC IS RC AT 22  
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
L8 STR



NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC I  
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE  
L10 9243 SEA FILE=REGISTRY SSS FUL L8  
L13 114 SEA FILE=REGISTRY SUB=L10 SSS FUL L3  
L20 0 SEA FILE=BEILSTEIN ABB=ON L13

=> fil hcap  
FILE 'HCAPLUS' ENTERED AT 14:07:54 ON 25 AUG 2006

=> d 115 1-5 ibib abs hitstr hitind

L15 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:703445 HCAPLUS  
DOCUMENT NUMBER: 145:167104  
TITLE: Preparation of 4-phenyltetrahydroisoquinolines  
as transport protein NHE-3 inhibitors  
INVENTOR(S): Heinelt, Uwe; Lang, Hans-Jochen; Wirth, Klaus;  
Licher, Thomas; Hofmeister, Armin  
PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland GmbH, Germany  
SOURCE: PCT Int. Appl., 127 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2006074813 A1 20060720 WO 2005-EP14127  
 2005  
 1230

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG,  
 ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
 KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
 LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,  
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,  
 HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL,  
 SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

DE 102005001411 A1 20060727 DE 2005-102005001411  
 2005  
 0112

PRIORITY APPLN. INFO.: DE 2005-102005001411A  
 2005  
 0112

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT  
 \*


AB The invention relates to the compds. of formula (I), wherein R1 to R8, W, X and Z are defined as in the claims. Title compds. I [R1-R4 = independently H, F, Cl, Br, NO<sub>2</sub>, NH-CH<sub>3</sub>, etc.; R5 = H, cyclo/alkyl; R6 = H, OH, F, CF<sub>3</sub>, cyclo/alkyl; R7, R8 = independently H, F, Br, CO<sub>2</sub>H and derivs., NH<sub>2</sub> and derivs., etc.; W = X = CO, SO<sub>2</sub>; Z = CO, a bond; and their pharmaceutically acceptable salts] were prepared as transport protein NHE-3 inhibitors. Thus, reacting 4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylamine with Et isocyanatoacetate, followed by cyclization gave tetrahydroisoquinoline II•HCl. In transport protein NHE-3 inhibition assays, 21-examples of compds. I exhibited IC<sub>50</sub> values ranging from 0.047-12.3 μM. I are useful for treating renal diseases, such as acute or chronic renal failure, biliary dysfunction and respiratory disorders such as snoring or sleep apnea, etc (no data).

IT 900570-96-9P 900570-97-0P 900571-08-6P  
 900571-09-7P 900571-10-0P 900571-13-3P  
 (intermediate; preparation of phenyltetrahydroisoquinolines as transport protein NHE-3 inhibitors)

RN 900570-96-9 HCAPLUS

CN Butanamide, N-[2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 900570-97-0 HCAPLUS

CN Butanamide, 4-chloro-N-[2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isquinolinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 900571-08-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl


RN 900571-09-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 900571-10-0 HCAPLUS  
 CN Acetamide, N-[2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 900571-13-3 HCAPLUS  
 CN Acetic acid, [2-[[2-[(4R)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]amino]-2-oxoethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 900571-12-2  
 CMF C20 H20 Cl2 N2 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1  
 IT 33924-45-7P, 2-Bromo-1-bromomethyl-4-chlorobenzene 900570-95-8P,  
 [3-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-  
 yl)phenyl]ureido]acetic acid ethyl ester hydrochloride  
 900570-96-9P 900570-97-0P 900570-98-1P  
 900570-99-2P 900571-00-8P, 1-(2-Aminophenyl)-2-[cyclopropyl(2,4-  
 dichlorobenzyl)amino]ethanol 900571-07-5P 900571-08-6P  
 900571-09-7P 900571-10-0P 900571-13-3P  
 900571-14-4P 900571-15-5P 900571-16-6P, N-[2-[2-[(2,4-  
 Dichlorobenzyl)amino]-1-hydroxyethyl]phenyl]acetamide  
 900571-17-7P, 1-(2-Aminophenyl)-2-[(2,4-  
 dichlorobenzyl)amino]ethanol 900571-18-8P 900571-19-9P  
 900571-24-6P, (2-Bromo-4-chlorobenzyl)methylamine 900571-25-7P,  
 N-[2-[2-[(2-Bromo-4-chlorobenzyl)(methyl)amino]acetyl]phenyl]aceta-  
 mide 900571-26-8P, N-[2-[2-[(2-Bromo-4-  
 chlorobenzyl)(methyl)amino]-1-hydroxyethyl]phenyl]acetamide  
 900571-27-9P, 1-(2-Aminophenyl)-2-[(2-bromo-4-  
 chlorobenzyl)(methyl)amino]ethanol 900571-28-0P,  
 2-(8-Bromo-6-chloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-  
 yl)phenylamine  
 (intermediate; preparation of phenyltetrahydroisoquinolines as  
 transport protein NHE-3 inhibitors)


REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE  
 IN THE RE FORMAT

L15 ANSWER 2 OF 5 HCPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:292722 HCPLUS  
 DOCUMENT NUMBER: 144:350556

TITLE: Preparation of 4-phenyltetrahydroisoquinolines  
as transport protein NHE-1 inhibitors  
INVENTOR(S): Lang, Hans-Jochen; Heinelt, Uwe; Wirth, Klaus;  
Licher, Thomas; Hofmeister, Armin  
PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006032372	A1	20060330	WO 2005-EP9654	2005 0908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004046492	A1	20060330	DE 2004-102004046492	2004 0923
RITY APPLN. INFO.:			DE 2004-102004046492A	2004 0923

OTHER SOURCE(S) : MARPAT 144:350556  
GI




AB Title compds. I [R1, R2, R3, R4 = H, halo, CN, etc.; R5 = H, alkyl, cycloalkyl, etc.; R6 = OH, F, CF<sub>3</sub>, etc.; R7 = H, alkyl, cycloalkyl, etc.; R8, R9 = H, F, OH, etc.; R10 = H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>] and their pharmaceutically acceptable salts were prepared. For example, ammonolysis of cyclobutene II [Y = OEt] afforded claimed phenyltetrahydroisoquinoline II [Y = NH<sub>2</sub>]. In transport protein NHE-1 inhibition assays, 22-examples of compds. I exhibited IC<sub>50</sub> values ranging from 0.031-8.0 μM.

IT 881315-44-2P

(preparation of phenyltetrahydroisoquinolines as transport protein NHE-1 inhibitors)

RN 881315-44-2 HCPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)-3-methylphenyl]- (9CI) (CA INDEX NAME)



CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1

IT 881315-41-9P 881315-44-2P

(preparation of phenyltetrahydroisoquinolines as transport protein NHE-1 inhibitors)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 5 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:822748 HCPLUS

DOCUMENT NUMBER: 141:332066

TITLE: Preparation of 4-phenyltetrahydroisoquinolines as NHE-3 sodium-proton exchanger inhibitors

INVENTOR(S): Hofmeister, Armin; Heinelt, Uwe; Lang, Hans-Jochen; Frick, Wendelin; Bleich, Markus; Wirth, Klaus

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 49 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
-----	-----	-----	-----	-----
DE 10312963	A1	20041007	DE 2003-10312963	

AU 2004224242	A1	20041007	AU 2004-224242	2003 0324
CA 2519658	AA	20041007	CA 2004-2519658	2004 0311
WO 2004085404	A1	20041007	WO 2004-EP2497	2004 0311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1613600	A1	20060111	EP 2004-719379	2004 0311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008744	A	20060418	BR 2004-8744	2004 0311
CN 1798737	A	20060705	CN 2004-80007871	2004 0311
US 2005009863	A1	20050113	US 2004-807781	2004 0324
NO 2005004876	A	20051206	NO 2005-4876	2005 1021
PRIORITY APPLN. INFO.:				
DE 2003-10312963				A 2003 0324
US 2003-493859P				P 2003 0808
WO 2004-EP2497				W 2004 0311
OTHER SOURCE(S): MARPAT 141:332066 GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT

\*


AB Title compds. I [R1, R2, R3, R4 = H, halo, CN, etc.; R5 = H, alkyl, cycloalkyl, etc.; R6 = H, OH, halo, etc.; R7, R8, R9 = CH<sub>2</sub>, O, OCO, etc.;] and their pharmaceutically acceptable salts were prepared. For example, N-acylation of aniline II, e.g., prepared from 2,4-dichlorobenzylmethylamine in 5-steps, with penta-O-acetyl-D-gluconoyl chloride, followed by acetate hydrolysis, afforded claimed isoquinoline III. In NHE-3 sodium-proton exchanger inhibition assays, 4-examples of compds. I exhibited IC<sub>50</sub> values ranging from 0.0036-0.1594 μM. Compds. I are claimed useful for the treatment of acute or chronic kidney failure.

IT 771576-93-3P 771576-94-4P 771576-95-5P  
 771576-96-6P 771576-97-7P 771576-98-8P  
 771577-24-3P 771577-25-4P 771577-26-5P  
 771577-28-7P 771577-34-5P 771578-00-8P  
 (preparation of phenyltetrahydroisoquinolines as NHE-3 sodium-proton exchanger inhibitors)

RN 771576-93-3 HCAPLUS

CN D-Gluconamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771576-94-4 HCAPLUS

CN D-Gluconamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771576-95-5 HCAPLUS

CN D-Gluconamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771576-96-6 HCAPLUS

CN D-Gluconamide, N-[3-[(4R)-2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]propanoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771576-97-7 HCAPLUS

CN D-Gluconamide, N-[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771576-98-8 HCAPLUS

CN D-Gluconamide, N-[3-[(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 771577-24-3 HCPLUS

CN Pentanamide, 2-amino-5-[(aminoiminomethyl)amino]-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 771577-25-4 HCPLUS

CN Pentanamide, 2-amino-5-[(aminoiminomethyl)amino]-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771577-26-5 HCPLUS

CN 1H-Imidazole-4-propanamide,  $\alpha$ -amino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771577-28-7 HCPLUS

CN D-Gluconamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771577-34-5 HCAPLUS

CN D-Gluconamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 771578-00-8 HCAPLUS

CN 1H-Imidazole-4-propanamide,  $\alpha$ -amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 543734-46-9P 771577-27-6P 771577-29-8P  
 771577-33-4P 771577-55-0P  
 (preparation of phenyltetrahydroisoquinolines as NHE-3 sodium-proton  
 exchanger inhibitors)  
 RN 543734-46-9 HCAPLUS  
 CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-  
 isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 771577-27-6 HCAPLUS  
 CN D-Gluconamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-  
 isoquinolinyl)phenyl]-, 2,3,4,5,6-pentaacetate (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



RN 771577-29-8 HCAPLUS

CN D-Gluconamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, 2,3,4,5,6-pentaacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771577-33-4 HCAPLUS

CN D-Gluconamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, 2,3,4,5,6-pentaacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 771577-55-0 HCPLUS

CN 11-Oxa-2,4,9-triazatridecanoic acid, 8-[[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]amino]carbonyl]-3-imino-12,12-dimethyl-10-oxo-, 1,1-dimethylethyl ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D217-14

ICS C07D401-12; A61K031-47; A61P013-00

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1

IT 771576-93-3P 771576-94-4P 771576-95-5P

771576-96-6P 771576-97-7P 771576-98-8P

771576-99-9P 771577-00-5P 771577-01-6P 771577-02-7P

771577-03-8P 771577-04-9P 771577-05-0P 771577-06-1P

771577-07-2P 771577-08-3P 771577-09-4P 771577-10-7P

771577-11-8P 771577-12-9P 771577-13-0P 771577-14-1P

771577-15-2P 771577-16-3P 771577-17-4P 771577-18-5P

771577-19-6P 771577-20-9P 771577-21-0P 771577-22-1P

771577-23-2P 771577-24-3P 771577-25-4P

771577-26-5P 771577-28-7P 771577-34-5P

771577-35-6P 771577-36-7P 771577-37-8P 771577-39-0P

771577-41-4P 771578-00-8P

(preparation of phenyltetrahydroisoquinolines as NHE-3 sodium-proton exchanger inhibitors)

IT 4688-64-6P, N-[2-(2-Bromoacetyl)phenyl]acetamide 21675-02-5P,  
 N-[4-(2-Bromoacetyl)phenyl]acetamide 30071-93-3P,  
 1-[3,5-Bis(trifluoromethyl)phenyl]ethanone 131805-94-2P,  
 1-[3,5-Bis(trifluoromethyl)phenyl]-2-bromoethanone  
 543734-46-9P 543734-76-5P 543735-10-0P 543737-13-9P,  
 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoic acid 543739-85-1P 771577-27-6P  
 771577-29-8P 771577-30-1P 771577-31-2P 771577-32-3P  
 771577-33-4P 771577-38-9P 771577-40-3P 771577-43-6P  
 771577-44-7P 771577-46-9P 771577-47-0P, (R)-3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylamine  
 771577-48-1P, (S)-3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylamine 771577-49-2P  
 771577-50-5P 771577-51-6P 771577-53-8P 771577-55-0P  
 (preparation of phenyltetrahydroisoquinolines as NHE-3 sodium-proton exchanger inhibitors)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 5 HCPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:506576 HCPLUS

DOCUMENT NUMBER: 139:69164

TITLE: Preparation of substituted 4-phenyltetrahydroisoquinolinium salts as inhibitors of cellular sodium-proton antiporters

INVENTOR(S): Hofmeister, Armin; Lang, Hans-Jochen; Heinelt, Uwe; Bleich, Markus; Wirth, Klaus

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: Ger. Offen., 16 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10163914	A1	20030703	DE 2001-10163914	2001 1222
CA 2471217	AA	20030710	CA 2002-2471217	2002 1209
WO 2003055880	A2	20030710	WO 2002-EP13922	2002 1209

WO 2003055880 A3 20031106  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
 MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
 SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,


AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002361028	A1	20030715	AU 2002-361028	
				2002
				1209
EP 1465870	A2	20041013	EP 2002-795126	
				2002
				1209
EP 1465870	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005524616	T2	20050818	JP 2003-556410	
				2002
				1209
AT 325100	E	20060615	AT 2002-795126	
				2002
				1209
US 2003171580	A1	20030911	US 2002-324041	
				2002
				1220
US 6703405	B2	20040309		
PRIORITY APPLN. INFO.:			DE 2001-10163914	A
				2001
				1222
			US 2002-353614P	P
				2002
				0201
			WO 2002-EP13922	W
				2002
				1209

OTHER SOURCE(S) :

MARPAT 139:69164

GI



I

AB 4-Phenyltetrahydroisoquinolinium salts I [substituted Ph; R<sup>1</sup>-R<sup>4</sup> = H, F, Cl, I, Br, CN, NO<sub>2</sub>, (un)substituted alkyl, alkoxy, alkoxy carbonyl, acyloxy, acyl, OPh, phenylalkoxy, heteroaryl, CONH<sub>2</sub>, OH, NH<sub>2</sub>, R<sup>5</sup>, R<sup>6</sup> = (un)substituted alkyl; NR<sup>5</sup>R<sup>6</sup> = heterocyclic; R<sup>7</sup> = H, F, Cl, Br, I, (un)substituted alkyl, alkoxy, acyloxy; Y = F, Cl, Br, I, OH, carboxylic sulfonic acid anion] were prepared. They are inhibitors of the cellular sodium proton antiporters. They affect the serum lipoproteins and can therefore be used for the prophylaxis and treatment of atherosclerotic

conditions. Thus, 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>NH<sub>2</sub> was treated with BrCH<sub>2</sub>COPh to give 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>NHCH<sub>2</sub>COPh, which was reduced to the alc., cyclized, and quaternized to give I [R = Ph, R<sub>1</sub>, R<sub>3</sub> = H, R<sub>2</sub>, R<sub>4</sub> = Cl, R<sub>5</sub>, R<sub>6</sub> = Me; Y = CF<sub>3</sub>CO<sub>2</sub>] which had an IC<sub>50</sub> for inhibition of the sodium-proton exchanger NHE3.


IT 552290-31-0P 552290-32-1P 552290-33-2P

552290-34-3P 552290-35-4P

(preparation of substituted 4-phenyltetrahydroisoquinolinium salts as inhibitors of cellular sodium-proton antiporters)

RN 552290-31-0 HCPLUS

CN Isoquinolinium, 4-[4-(acetylamino)phenyl]-6,8-dichloro-1,2,3,4-tetrahydro-2,2-dimethyl-, iodide (9CI) (CA INDEX NAME)




● I<sup>-</sup>

RN 552290-32-1 HCPLUS

CN Isoquinolinium, 4-[4-(acetylamino)phenyl]-6,8-dichloro-1,2,3,4-tetrahydro-2,2-dimethyl-, iodide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




● I<sup>-</sup>

RN 552290-33-2 HCAPLUS

CN Isoquinolinium, 4-[4-(acetylamino)phenyl]-6,8-dichloro-1,2,3,4-tetrahydro-2,2-dimethyl-, chloride, (+)- (9CI) (CA INDEX NAME)


Rotation (+).

●  $\text{Cl}^-$ 

RN 552290-34-3 HCAPLUS

CN Isoquinolinium, 4-[4-(acetylamino)phenyl]-6,8-dichloro-1,2,3,4-tetrahydro-2,2-dimethyl-, iodide, (-)- (9CI) (CA INDEX NAME)


Rotation (-).

●  $\text{I}^-$ 

RN 552290-35-4 HCAPLUS


CN Isoquinolinium, 4-[4-(acetylamino)phenyl]-6,8-dichloro-1,2,3,4-tetrahydro-2,2-dimethyl-, chloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● Cl<sup>-</sup>

IT 543734-46-9P  
 (preparation of substituted 4-phenyltetrahydroisoquinolinium salts  
 as inhibitors of cellular sodium-proton antiporters)  
 RN 543734-46-9 HCPLUS  
 CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-  
 isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)



IC ICM C07D217-04  
 ICS A61K031-47  
 CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 11  
 IT 552290-27-4P 552290-30-9P 552290-31-0P  
 552290-32-1P 552290-33-2P 552290-34-3P  
 552290-35-4P  
 (preparation of substituted 4-phenyltetrahydroisoquinolinium salts  
 as inhibitors of cellular sodium-proton antiporters)  
 IT 543734-46-9P 543734-48-1P 543737-21-9P,  
 6,8-Dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline  
 543738-38-1P 543739-86-2P, 2-[(2,4-Dichlorobenzyl)-N-  
 methylamino]-1-phenylethanone 543739-87-3P, 2-[(2,4-  
 Dichlorobenzyl)-N-methylamino]-1-phenylethanol 552290-36-5P  
 552290-37-6P  
 (preparation of substituted 4-phenyltetrahydroisoquinolinium salts  
 as inhibitors of cellular sodium-proton antiporters)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE  
IN THE RE FORMAT

L15 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:454295 HCAPLUS  
DOCUMENT NUMBER: 139:52892  
TITLE: Preparation of 2-(2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyls as sodium ion proton antiporter (NHE) inhibitors  
INVENTOR(S): Hofmeister, Armin; Heinelt, Uwe; Lang, Hans-Jochen; Bleich, Markus; Wirth, Klaus; Gekle, Michael  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: PCT Int. Appl., 304 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2003048129	A1	20030612	WO 2002-EP12990	2002 1120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	CA 2469385	AA 20030612	CA 2002-2469385 2002 1120
AU 2002356689	A1	20030617	AU 2002-356689 2002 1120	
EP 1453810	A1	20040908	EP 2002-804183 2002 1120	
BR 2002014753	A	20041214	BR 2002-14753 2002 1120	
CN 1617856	A	20050518	CN 2002-827887 2002 1120	
JP 2005515205	T2	20050526	JP 2003-549321 2002 1120	

US 2004044211	A1	20040304	US 2002-309352	
				2002
				1204
US 6911453	B2	20050628		
ZA 2004003711	A	20050609	ZA 2004-3711	
				2004
				0514
NO 2004002158	A	20040827	NO 2004-2158	
				2004
				0525
US 2005009864	A1	20050113	US 2004-866843	
				2004
				0614
PRIORITY APPLN. INFO.:			DE 2001-10159714	A
				2001
				1205
		US 2002-353513P		P
				2002
				0201
		WO 2002-EP12990		W
				2002
				1120
		US 2002-309352		A3
				2002
				1204

OTHER SOURCE(S) : MARPAT 139:52892  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT  
\*

AB Title compds. I [R1, R2, R3, R4 = H, halo, CN, etc.; R5 = H, CpH2p+1, CssH2ss-1, etc.; p = 1-8; ss = 3-8; R6 = H, halo, OH, etc.; R7, R8, R9 = Ov-SOw-R23; v = 0, 1; w = 0-2, R23 = OH, CnnH2nn+1, CmmH2mm-1, etc.; nn = 1-8] and their pharmaceutically acceptable salts were prepared. For example, acid catalyzed intramol. Pictet Spengler cyclization of benzyl alc. II, prepared from N-methyl-2,4-dichlorobenzylamine in 3-steps, afforded claimed phenyltetrahydroisoquinoline III. In proton sodium antiporting protein (NHE3) inhibition studies, 27-examples of compds. I exhibited IC50 values ranging from 0.024-1.507  $\mu$ M, e.g., the IC50 value of phenyltetrahydroisoquinoline III hydrochloride was 0.075  $\mu$ M. Compds. I can also influence serum lipoproteins and can be used for the regression of atherosclerotic alterations.

IT 543734-46-9P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543734-88-9P, N-[4-(6-Bromo-8-chloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543734-90-3P 543734-92-5P 543734-94-7P, N-[4-[8-Chloro-2-methyl-6-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-4-yl]phenyl]acetamide 543734-96-9P, N-[4-[8-Chloro-6-(cyclopropylmethylamino)-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]phenyl]acetamide 543735-07-5P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-


tetrahydroisoquinolin-4-yl)phenyl]acetamide 543735-12-2P  
, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543735-14-4P,  
N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543735-16-6P, Pentanoic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-17-7P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]isobutyramide 543735-19-9P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,2-dimethylpropionamide 543735-27-9P 543735-39-3P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543735-41-7P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543735-42-8P, Pentanoic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-44-0P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]isobutyramide 543735-46-2P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,2-dimethylpropionamide 543735-54-2P 543735-64-4P, N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543735-66-6P, N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543735-68-8P, Pentanoic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-69-9P 543735-71-3P, N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,2-dimethylpropionamide 543735-76-8P 543736-00-1P, 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543736-01-2P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-methylaminoacetamide 543736-02-3P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-dimethylaminoacetamide 543736-03-4P, 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543736-04-5P, 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543736-05-6P, 2,6-Diaminohexanoic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-19-2P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-methylaminoacetamide 543736-20-5P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-dimethylaminoacetamide 543736-21-6P, 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543736-22-7P, 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543736-23-8P, 2,6-Diaminohexanoic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543737-09-3P, N-[3-(6,8-Difluoro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543737-44-6P 543737-65-1P 543737-66-2P 543737-71-9P 543737-72-0P 543737-73-1P 543737-74-2P 543737-79-7P 543737-80-0P 543737-81-1P 543737-82-2P 543737-83-3P 543737-90-2P 543737-91-3P 543737-92-4P 543737-93-5P 543737-94-6P 543737-98-0P 543738-04-1P 543738-05-2P 543738-06-3P 543738-07-4P 543738-08-5P 543738-12-1P

543738-23-4P 543738-24-5P 543738-52-9P  
 543738-53-0P 543738-54-1P 543738-56-3P  
 543738-58-5P 543738-60-9P 543738-75-6P  
 543738-76-7P 543738-78-9P 543738-80-3P  
 543738-82-5P 543739-80-6P 543739-83-9P

(drug candidate; preparation of phenyltetrahydroisoquinolines as sodium ion proton antiporter inhibitors)


RN 543734-46-9 HCPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543734-88-9 HCPLUS

CN Acetamide, N-[4-(6-bromo-8-chloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543734-90-3 HCPLUS

CN Acetamide, N-[4-[8-chloro-1,2,3,4-tetrahydro-2-methyl-6-(1-pyrrolidinyl)-4-isoquinolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 543734-92-5 HCAPLUS

CN Acetamide, N-[4-[8-chloro-1,2,3,4-tetrahydro-2-methyl-6-(4-morpholinyl)-4-isouquinolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 543734-94-7 HCAPLUS

CN Acetamide, N-[4-[8-chloro-1,2,3,4-tetrahydro-2-methyl-6-(4-methyl-1-piperazinyl)-4-isouquinolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 543734-96-9 HCAPLUS

CN Acetamide, N-[4-[8-chloro-6-[(cyclopropylmethyl)amino]-1,2,3,4-tetrahydro-2-methyl-4-isouquinolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 543735-07-5 HCPLUS

CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-12-2 HCPLUS

CN Propanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-14-4 HCPLUS

CN Butanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-16-6 HCAPLUS

CN Pentanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-17-7 HCAPLUS

CN Propanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 543735-19-9 HCAPLUS

CN Propanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 543735-27-9 HCPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 543735-39-3 HCPLUS

CN Propanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-41-7 HCAPLUS

CN Butanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-42-8 HCAPLUS

CN Pentanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543735-44-0 HCAPLUS

CN Propanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 543735-46-2 HCAPLUS

CN Propanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 543735-54-2 HCAPLUS

CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 543735-64-4 HCAPLUS


CN Propanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 543735-66-6 HCAPLUS


CN Butanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-

isoquinolinyl)phenyl] - (9CI) (CA INDEX NAME)




RN 543735-68-8 HCAPLUS

CN Pentanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl] - (9CI) (CA INDEX NAME)




RN 543735-69-9 HCAPLUS

CN Propanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 543735-71-3 HCAPLUS

CN Propanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 543735-76-8 HCAPLUS

CN Acetamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 543736-00-1 HCAPLUS

CN Acetamide, 2-amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543736-01-2 HCAPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 543736-02-3 HCPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 543736-03-4 HCPLUS

CN Propanamide, 2-amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543736-04-5 HCPLUS

CN Butanamide, 2-amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543736-05-6 HCAPLUS

CN Hexanamide, 2,6-diamino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543736-19-2 HCAPLUS

CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 543736-20-5 HCAPLUS

CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 543736-21-6 HCAPLUS

CN Propanamide, 2-amino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543736-22-7 HCAPLUS

CN Butanamide, 2-amino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543736-23-8 HCAPLUS

CN Hexanamide, 2,6-diamino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 543737-09-3 HCAPLUS

CN Acetamide, N-[3-(6,8-difluoro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 543737-44-6 HCAPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 543737-65-1 HCPLUS

CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (-) - (9CI) (CA INDEX NAME)


Rotation (-).



RN 543737-66-2 HCPLUS


CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (+) - (9CI) (CA INDEX NAME)

Rotation (+).



RN 543737-71-9 HCAPLUS

CN Acetamide, N-[4-[8-chloro-1,2,3,4-tetrahydro-2-methyl-6-(1-pyrrolidinyl)-4-isoquinolinyl]phenyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl


RN 543737-72-0 HCAPLUS

CN Acetamide, N-[4-[8-chloro-1,2,3,4-tetrahydro-2-methyl-6-(4-morpholinyl)-4-isoquinolinyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 543734-92-5

CMF C22 H26 Cl N3 O2




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 543737-73-1 HCAPLUS  
 CN Acetamide, N-[4-[8-chloro-1,2,3,4-tetrahydro-2-methyl-6-(4-methyl-1-piperazinyl)-4-isoquinolinyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 543737-74-2 HCAPLUS  
 CN Acetamide, N-[4-[8-chloro-6-[(cyclopropylmethyl)amino]-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 543737-79-7 HCAPLUS

CN Propanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543735-12-2


CMF C19 H20 Cl2 N2 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 543737-80-0 HCAPLUS  
CN Butanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-14-4  
CMF C20 H22 C12 N2 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 543737-81-1 HCAPLUS  
CN Pentanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543735-16-6  
CMF C21 H24 C12 N2 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 543737-82-2 HCAPLUS  
 CN Propanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543735-17-7  
CMF C20 H22 Cl2 N2 O

CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 543737-83-3 HCAPLUS  
 CN Propanamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-19-9  
 CMF C21 H24 Cl2 N2 O



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 543737-90-2 HCAPLUS  
 CN Propanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-39-3  
CMF C19 H20 Cl2 N2 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 543737-91-3 HCAPLUS  
CN Butanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 543735-41-7  
CMF C20 H22 Cl2 N2 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 543737-92-4 HCAPLUS  
CN Pentanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 543735-42-8  
CMF C21 H24 Cl2 N2 O

CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 543737-93-5 HCAPLUS  
CN Propanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-44-0  
 CMF C20 H22 Cl2 N2 O



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2




RN 543737-94-6 HCAPLUS  
 CN Propanamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 543735-46-2  
 CMF C21 H24 Cl2 N2 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 543737-98-0 HCAPLUS  
CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2,2-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 543735-54-2  
CMF C18 H15 Cl2 F3 N2 O

CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 543738-04-1 HCAPLUS  
CN Propanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-64-4  
 CMF C19 H20 Cl2 N2 O



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 543738-05-2 HCAPLUS

CN Butanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-66-6  
 CMF C20 H22 Cl2 N2 O



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 543738-06-3 HCAPLUS

CN Pentanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543735-68-8


CMF C21 H24 Cl2 N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 543738-07-4 HCAPLUS

CN Propanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543735-69-9

CMF C20 H22 Cl2 N2 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 543738-08-5 HCAPLUS  
 CN Propanamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 543735-71-3  
CMF C21 H24 Cl2 N2 O

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 543738-12-1 HCAPLUS

CN Acetamide, N-[2-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2,2-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543735-76-8


CMF C18 H15 Cl2 F3 N2 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 543738-23-4 HCAPLUS

CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 543738-24-5 HCPLUS

CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 543738-52-9 HCPLUS

CN Acetamide, 2-amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543736-00-1

CMF C18 H19 Cl2 N3 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 543738-53-0 HCAPLUS  
 CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(methylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543736-01-2  
CMF C19 H21 Cl2 N3 O

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 543738-54-1 HCPLUS  
CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(dimethylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543736-02-3  
CMF C20 H23 Cl2 N3 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 543738-56-3 HCPLUS  
CN Propanamide, 2-amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 543738-55-2  
 CMF C19 H21 Cl2 N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 543738-58-5 HCPLUS  
 CN Butanamide, 2-amino-N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543738-57-4  
 CMF C20 H23 Cl2 N3 O

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2

RN 543738-60-9 HCPLUS  
 CN Hexanamide, 2,6-diamino-N- [4- (6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl] -, (2S) -, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 543738-59-6  
CMF C22 H28 Cl2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 543738-75-6 HCAPLUS


KN 343738-73-8 ICAPLUS  
CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(methylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543736-19-2  
CMF C19 H21 C12 N3 O




CM 2


CRN 76-05-1  
CMF C2 H F3 O2

RN 543738-76-7 HCPLUS  
 CN Acetamide, N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2-(dimethylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543736-20-5  
CMF C20 H23 Cl2 N3 O

CM 2


CRN 76-05-1  
CMF C2 H F3 O2

RN 543738-78-9 HCPLUS  
 CN Propanamide, 2-amino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 543738-77-8  
 CMF C19 H21 Cl2 N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 543738-80-3 HCAPLUS  
 CN Butanamide, 2-amino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543738-79-0  
 CMF C20 H23 Cl2 N3 O

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 543738-82-5 HCPLUS  
CN Hexanamide, 2,6-diamino-N-[3-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 543738-81-4  
CMF C22 H28 Cl2 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

RN 543739-80-6 HCPLUS  
 CN Acetamide, N-[3-(6,8-difluoro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 543739-83-9 HCPLUS  
 CN Acetamide, N-[4-(6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl)phenyl]-2,2,2-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 543735-27-9  
CMF C18 H15 Cl2 F3 N2 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

IC ICM C07D217-22  
 ICS C07D401-12; C07D403-12; C07D417-12; C07D409-12; A61K031-47;  
 A61P009-12  
 CC 27-17 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s) : 1  
 IT 24526-64-5P, 2-Methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-ylamine 55774-26-0P, 4-(8-Amino-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenol 60520-18-5P,  
 5-(8-Amino-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-2-methoxyphenol 63806-80-4P, N-(2-Methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-yl)acetamide 69275-19-0P,  
 4-(8-Amino-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzol-1,2-diol 69406-45-7P, 4-(3,4-Dichlorophenyl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-8-ylamine 99087-42-0P 109086-13-7P  
 118411-63-5P 128942-68-7P 129010-57-7P 338999-84-1P  
 339001-35-3P 543734-46-9P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide  
 543734-48-1P, 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide 543734-50-5P,  
 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide 543734-52-7P, 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N-dimethylbenzenesulfonamide  
 543734-54-9P 543734-56-1P, 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoic acid 543734-58-3P,  
 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-ethylbenzamide 543734-60-7P, 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-propylbenzamide 543734-62-9P,  
 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2-dimethylaminoethyl)benzamide 543734-64-1P 543734-66-3P

543734-68-5P 543734-70-9P 543734-72-1P 543734-74-3P  
 543734-76-5P, 4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylamine 543734-78-7P  
 543734-80-1P, 1-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-methylthiourea 543734-82-3P  
 543734-84-5P 543734-86-7P, N-[4-(2,6,8-Trimethyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543734-88-9P  
 , N-[4-(6-Bromo-8-chloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543734-90-3P 543734-92-5P  
 543734-94-7P, N-[4-[8-Chloro-2-methyl-6-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-4-yl]phenyl]acetamide  
 543734-96-9P, N-[4-[8-Chloro-6-(cyclopropylmethylamino)-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]phenyl]acetamide  
 543734-98-1P, 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-2-hydroxybenzoic acid 543735-00-8P,  
 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-2-hydroxy-N-methylbenzamide 543735-02-0P, 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-ethyl-2-hydroxybenzamide  
 543735-04-2P, 5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2-dimethylaminoethyl)-2-hydroxybenzamide 543735-06-4P, N-[5-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]guanidine  
 543735-07-5P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543735-09-7P,  
 3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylamine 543735-10-0P, 2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylamine 543735-12-2P,  
 N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543735-14-4P,  
 N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543735-16-6P, Pentanoic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-17-7P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]isobutyramide  
 543735-19-9P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,2-dimethylpropionamide  
 543735-21-3P, Cyclopropancarboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-23-5P,  
 Cyclobutancarboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-25-7P,  
 Cyclopentancarboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-27-9P  
 543735-29-1P, 1-Acetylpiriperidin-4-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide  
 543735-31-5P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]nicotinamide 543735-33-7P,  
 N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]methansulfonamide 543735-35-9P, Ethansulfonic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-37-1P 543735-39-3P,  
 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543735-41-7P,  
 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543735-42-8P, Pentanoic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-44-0P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]isobutyramide  
 543735-46-2P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,2-dimethylpropionamide 543735-48-4P, Cyclopropancarboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide

1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-50-8P,  
 Cyclobutancarboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-52-0P,  
 Cyclopentancarboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-54-2P  
 543735-56-4P, 1-Acetyl piperidin-4-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide  
 543735-58-6P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]nicotinamide 543735-60-0P,  
 N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]methansulfonamide 543735-61-1P, Ethansulfonic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-62-2P 543735-64-4P,  
 N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543735-66-6P,  
 N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543735-68-8P, Pentanoic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-69-9P 543735-71-3P,  
 N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,2-dimethylpropionamide 543735-73-5P,  
 Cyclopropancarboxylic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-74-6P,  
 Cyclobutancarboxylic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-75-7P,  
 Cyclopentancarboxylic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-76-8P  
 543735-77-9P, 1-Acetyl piperidin-4-carboxylic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]methansulfonamide  
 543735-78-0P, N-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]methansulfonamide  
 543735-79-1P, Ethansulfonic acid-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-80-4P  
 543735-81-5P 543735-82-6P, 1-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-methylthiourea 543735-83-7P  
 543735-84-8P, 1-[2-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-methylthiourea 543735-85-9P  
 543735-86-0P 543735-87-1P, 1,2-Dimethyl-1H-imidazole-4-sulfonic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-88-2P, 1,2-Dimethyl-1H-imidazole-4-sulfonic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-89-3P  
 543735-90-6P, 5-Chloro-1,3-dimethyl-1H-pyrazol-4-sulfonic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543735-91-7P 543735-92-8P 543735-93-9P  
 543735-94-0P 543735-95-1P 543735-96-2P 543735-97-3P  
 543735-98-4P, 2-Chloro-5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonic acid amide  
 543735-99-5P, 2-Methyl-4-phenyl-6,8-bis(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin 543736-00-1P, 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]acetamide 543736-01-2P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-methylaminoacetamide 543736-02-3P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-dimethylaminoacetamide 543736-03-4P,  
 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543736-04-5P,  
 2-Amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543736-05-6P, 2,6-Diaminohexanoic

acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-06-7P, Pyrrolidine-2-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-07-8P, N-[4-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]isonicotinamide 543736-08-9P, 1H-Pyrrole-3-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-09-0P, 1H-Pyrrol-2-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-10-3P, 1-Methylpiperidin-4-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-11-4P, 1,4-Dimethyl-1H-pyrrol-2-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-12-5P, 4-Nitro-1H-pyrrol-2-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-13-6P, 2,5-Dimethyl-1H-pyrrol-3-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-14-7P, 1H-Imidazol-4-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-15-8P 543736-16-9P, 3,5-Dimethyl-1H-pyrazol-4-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-17-0P, 1H-Pyrazol-4-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-18-1P, 3-Trifluoromethyl-1H-pyrazol-4-carboxylic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-19-2P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-methylaminoacetamide 543736-20-5P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-dimethylaminoacetamide 543736-21-6P, 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]propionamide 543736-22-7P, 2-Amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]butyramide 543736-23-8P, 2,6-Diaminohexanoic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-24-9P, Pyrrolidin-2-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-25-0P, N-[3-(6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]isonicotinamide 543736-26-1P, 1H-Pyrrol-3-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-27-2P, 1H-Pyrrol-2-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-28-3P, 1-Methylpiperidin-4-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-29-4P, 1,4-Dimethyl-1H-pyrrol-2-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-30-7P, 4-Nitro-1H-pyrrol-2-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-31-8P, 2,5-Dimethyl-1H-pyrrol-3-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-32-9P, 1H-Imidazol-4-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-33-0P 543736-34-1P, 3,5-Dimethyl-1H-pyrazol-4-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-35-2P, 1H-Pyrazol-4-carboxylic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-36-3P, 3-Trifluoromethyl-1H-pyrazol-4-

carboxylic acid- [3- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-37-4P,  
 1- [2- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-ethylthiourea 543736-38-5P, 1- [4- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-ethylthiourea 543736-39-6P, 1- [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-ethylthiourea 543736-40-9P  
 543736-41-0P, 4-Methylpiperazin-1-carboxylic acid- [3- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-42-1P, Piperidin-1-carboxylic acid- [3- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-43-2P, Morpholin-4-carboxylic acid- [3- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-44-3P, Pyrrolidin-1-carboxylic acid- [3- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-45-4P 543736-46-5P 543736-47-6P 543736-48-7P  
 543736-49-8P 543736-50-1P 543736-51-2P 543736-52-3P  
 543736-53-4P 543736-54-5P 543736-55-6P 543736-56-7P  
 543736-57-8P, 4-Methylpiperazin-1-carboxylic acid- [2- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-58-9P 543736-59-0P 543736-60-3P 543736-61-4P,  
 Piperidin-1-carboxylic acid- [2- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-62-5P,  
 Morpholin-4-carboxylic acid- [2- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-63-6P,  
 Pyrrolidin-1-carboxylic acid- [2- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-64-7P  
 543736-65-8P, 4-Methylpiperazin-1-carboxylic acid- [4- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-66-9P, Pyrrolidin-1-carboxylic acid- [4- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-67-0P 543736-68-1P 543736-69-2P 543736-70-5P  
 543736-71-6P, Piperidin-1-carboxylic acid- [4- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-72-7P, Morpholin-4-carboxylic acid- [4- (6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide 543736-73-8P, N- [4- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]formamide 543736-74-9P,  
 [4- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]methylamine 543736-75-0P 543736-76-1P 543736-77-2P  
 543736-78-3P 543736-79-4P 543736-80-7P 543736-81-8P  
 543736-82-9P 543736-83-0P, N- [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]formamide 543736-84-1P,  
 [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]methylamine 543736-85-2P 543736-86-3P 543736-87-4P  
 543736-88-5P 543736-89-6P 543736-90-9P 543736-92-1P  
 543736-93-2P 543736-94-3P 543736-95-4P 543736-96-5P  
 543736-97-6P, [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]carbamate methyl ester  
 543736-98-7P, [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]carbamate ethyl ester  
 543736-99-8P, [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]carbamate isopropyl ester  
 543737-00-4P 543737-01-5P, [4- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]carbamate methyl ester  
 543737-02-6P, [4- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]carbamate-isopropyl ester  
 543737-03-7P 543737-04-8P, [4- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]carbamide 543737-05-9P,  
 (R)-N- [3- (6,8-Dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-

yl)phenyl]methansulfonamide 543737-06-0P, (S)-N-[3-(6,8-Dichloro-  
 2-methyl-1,2,3,4-tetrahydroisoquinolin-4-  
 yl)phenyl]methansulfonamide 543737-07-1P 543737-08-2P  
**543737-09-3P**, N-[3-(6,8-Difluoro-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)phenyl]acetamide 543737-10-6P  
 543737-11-7P 543737-12-8P, 3-(6,8-Dichloro-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)benzoic acid ethyl ester  
 543737-13-9P, 3-(6,8-Dichloro-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)benzoic acid 543737-14-0P  
 543737-15-1P, Morpholin-4-carboxylic acid-[4-(6,8-dichloro-2-  
 methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]amide  
 543737-16-2P 543737-17-3P 543737-18-4P, 5-Bromothiophen-2-  
 sulfonic acid-[4-(6,8-dichloro-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)phenyl]amide 543737-19-5P,  
 5-Bromothiophen-2-sulfonic acid-[3-(6,8-dichloro-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)phenyl]amide 543737-21-9P,  
 6,8-Dichloro-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin  
 543737-22-0P, 2-(8-Amino-2-ethyl-1,2,3,4-tetrahydroisoquinolin-4-  
 yl)phenol 543737-23-1P, 2-(8-Amino-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)phenol 543737-24-2P 543737-25-3P,  
 4-(2,4-Dichlorophenyl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-8-  
 ylamine 543737-26-4P, 4-(3-Chlorophenyl)-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-8-ylamine 543737-27-5P,  
 2,4-Dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline  
 543737-28-6P, 2-Butyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-  
 ylamine 543737-29-7P 543737-30-0P, 2,6-Dimethyl-4-phenyl-  
 1,2,3,4-tetrahydroisoquinoline 543737-31-1P 543737-32-2P  
**543737-33-3P** 543737-34-4P

(drug candidate; preparation of phenyltetrahydroisoquinolines as  
 sodium ion proton antiporter inhibitors)

IT 543737-35-5P 543737-36-6P 543737-37-7P 543737-38-8P  
 543737-39-9P 543737-40-2P 543737-41-3P 543737-42-4P  
**543737-43-5P**, [4-(6,8-Dichloro-2-methyl-1,2,3,4-  
 tetrahydroisoquinolin-4-yl)phenyl]carbamate ethyl ester  
**543737-44-6P** 543737-45-7P 543737-46-8P 543737-48-0P  
 543737-50-4P 543737-51-5P 543737-52-6P 543737-53-7P  
 543737-54-8P 543737-55-9P 543737-56-0P 543737-57-1P  
 543737-58-2P 543737-59-3P 543737-60-6P 543737-61-7P  
 543737-62-8P 543737-63-9P 543737-64-0P **543737-65-1P**  
 543737-66-2P 543737-67-3P 543737-68-4P 543737-69-5P  
 543737-70-8P **543737-71-9P** **543737-72-0P**  
 543737-73-1P **543737-74-2P** 543737-75-3P  
 543737-76-4P 543737-77-5P 543737-78-6P **543737-79-7P**  
**543737-80-0P** **543737-81-1P** **543737-82-2P**  
 543737-83-3P 543737-84-4P 543737-85-5P 543737-86-6P  
 543737-87-7P 543737-88-8P 543737-89-9P **543737-90-2P**  
**543737-91-3P** **543737-92-4P** **543737-93-5P**  
 543737-94-6P 543737-95-7P 543737-96-8P 543737-97-9P  
 543737-98-0P 543737-99-1P 543738-00-7P 543738-01-8P  
 543738-02-9P 543738-03-0P **543738-04-1P**  
**543738-05-2P** **543738-06-3P** **543738-07-4P**  
 543738-08-5P 543738-09-6P 543738-10-9P 543738-11-0P  
 543738-12-1P 543738-13-2P 543738-14-3P 543738-15-4P  
 543738-16-5P 543738-17-6P 543738-18-7P 543738-19-8P  
 543738-20-1P 543738-21-2P 543738-22-3P **543738-23-4P**  
**543738-24-5P** 543738-25-6P 543738-26-7P 543738-27-8P  
 543738-28-9P 543738-29-0P 543738-30-3P 543738-31-4P  
 543738-32-5P 543738-33-6P 543738-34-7P 543738-35-8P  
 543738-36-9P 543738-37-0P 543738-38-1P 543738-40-5P  
 543738-42-7P 543738-43-8P 543738-44-9P 543738-45-0P

543738-46-1P 543738-47-2P 543738-48-3P 543738-49-4P  
 543738-50-7P 543738-51-8P 543738-52-9P  
 543738-53-0P 543738-54-1P 543738-56-3P  
 543738-58-5P 543738-60-9P 543738-62-1P  
 543738-63-2P 543738-64-3P 543738-65-4P 543738-66-5P  
 543738-67-6P 543738-68-7P 543738-69-8P 543738-70-1P  
 543738-71-2P 543738-72-3P 543738-73-4P 543738-74-5P  
 543738-75-6P 543738-76-7P 543738-78-9P  
 543738-80-3P 543738-82-5P 543738-84-7P  
 543738-85-8P 543738-86-9P 543738-87-0P 543738-89-2P  
 543738-90-5P 543738-93-8P 543738-96-1P 543738-98-3P  
 543739-01-1P 543739-03-3P 543739-05-5P 543739-07-7P  
 543739-09-9P 543739-11-3P 543739-13-5P 543739-15-7P  
 543739-17-9P 543739-18-0P 543739-19-1P 543739-20-4P  
 543739-21-5P 543739-22-6P 543739-23-7P 543739-24-8P  
 543739-25-9P 543739-26-0P 543739-27-1P 543739-28-2P  
 543739-29-3P 543739-30-6P 543739-31-7P 543739-32-8P  
 543739-33-9P 543739-34-0P 543739-35-1P 543739-36-2P  
 543739-37-3P 543739-38-4P 543739-39-5P 543739-40-8P  
 543739-41-9P 543739-42-0P 543739-43-1P 543739-44-2P  
 543739-45-3P 543739-46-4P 543739-47-5P 543739-48-6P  
 543739-49-7P 543739-50-0P 543739-51-1P 543739-52-2P  
 543739-53-3P 543739-54-4P 543739-55-5P 543739-56-6P  
 543739-57-7P 543739-58-8P 543739-59-9P 543739-60-2P  
 543739-61-3P 543739-62-4P 543739-63-5P 543739-64-6P  
 543739-65-7P 543739-66-8P 543739-67-9P 543739-68-0P  
 543739-69-1P 543739-70-4P 543739-71-5P 543739-72-6P  
 543739-73-7P 543739-74-8P 543739-75-9P 543739-76-0P  
 543739-77-1P 543739-78-2P 543739-79-3P 543739-80-6P  
 543739-81-7P 543739-82-8P 543739-83-9P  
 (drug candidate; preparation of phenyltetrahydroisoquinolines as  
 sodium ion proton antiporter inhibitors)


REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE  
IN THE RE FORMAT

=> fil marpat  
FILE 'MARPAT' ENTERED AT 14:08:41 ON 25 AUG 2006

=> d 118 1-6 ibib abs qhit


L18 ANSWER 1 OF 6 MARPAT COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 145:8036 MARPAT  
TITLE: Preparation of 4-phenyl substituted  
tetrahydroisoquinolines and their use to block  
reuptake of norepinephrine, dopamine, and  
serotonin  
INVENTOR(S): Molino, Bruce F.; Berkowitz, Barry; Cohen,  
Marlene  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 36 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006111393	A1	20060525	US 2004-994688	20041122
US 2006111396	A1	20060525	US 2005-284266	20051121
WO 2006057950	A2	20060601	WO 2005-US42110	20051121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-994688	20041122
GI				




AB The invention is related to a method of treating disorders including stress urinary incontinence, migraine, and neuropathic pain by administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound of formula (I) [R1 = (un)substituted alk(en/yn)yl, cycloalkyl/alkyl; R2 = H, alk(en/yn)yl, haloalkyl, etc.; R3, R4 = independently H, halo, OH and derivs., cyclo/alkyl, etc.; R5-R7 = independently H, NHCONH-alkyl and derivs., NH2 and derivs., etc.; R8 = H, halo, OH and derivs.; with provisos]. The invention is also related to the preparation of 4-Ph substituted tetrahydroisoquinolines I and analogs. E.g., reductive alkylation of m-methylbenzaldehyde with  $\alpha$ -[(methylamino)methyl]benzyl alc. and cyclization in DCM in the presence of 98% H2SO4 gave 2,7-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline. I are more selective for the norepinephrine transporter (NET) protein than the dopamine transporter (DAT) protein or serotonin transporter (SERT) proteins. Generally, I have a Ki ratio for DAT/NET and SERT/NET of at least about 2:1 and 20:1, resp.


MSTR 1



G1 = Me  
 G5 = F  
 G10 = 86



G11 = 11



G15 = 159

$\frac{C(O)\cdot G19}{159}$

Patent location: claim 1  
 Note: substitution is restricted  
 Note: or oxides, pharmaceutically acceptable  
 salts, solvates, or prodrugs  
 Stereochemistry: 7 - R or S

L18 ANSWER 2 OF 6 MARPAT COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 144:488538 MARPAT  
 TITLE: Preparation of hetero/aryl substituted  
 tetrahydroisoquinolines and their use to block  
 reuptake of norepinephrine, dopamine and  
 serotonin  
 INVENTOR(S): Molino, Bruce F.; Berkowitz, Barry; Cohen,  
 Marlene  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 23 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 2006111394	A1	20060525	US 2004-994956	20041122
US 2006111395	A1	20060525	US 2005-284264	20051121
WO 2006058016	A2	20060601	WO 2005-US42347	20051121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-994956 20041122  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT  
\*

AB The invention is related to a method of treating disorders including stress urinary incontinence, migraine, and neuropathic pain by administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound of formula (I) [R1 = (un)substituted alk(en/yn)yl, cycloalkyl/alkyl; R2 = H, alk(en/yn)yl, cycloalkyl/alkyl, haloalkyl; R3 = H, halo, OH and derivs., CN, alkyl, etc.; R4 = (un)substituted Ph, naphthyl, indenyl, pyrimidinyl, benzofuranyl, etc.; R5-R7 = independently H, halo, OH and derivs., CN, SH and derivs., (un)substituted alk(en/yn)yl, etc.; or R5CCR6 = -O-(CH2)2-O- and derivs.; R8 = H, halo, OH and derivs.]. The invention is also related to the preparation of 4-Ph substituted tetrahydroisoquinolines I, stereoisomers, and analogs. E.g., a 5-step synthesis starting from 3-iodobenzyl alc. was given for tetrahydroisoquinoline II. I are more selective for the norepinephrine transporter (NET) protein than the dopamine transporter (DAT) protein or serotonin transporter (SERT) proteins. Generally, I have a Ki ratio for DAT/NET and SERT/NET of at least about 2:1 and 20:1, resp.


MSTR 1



G1 = Me  
 G5 = F  
 G10 = 86



G11 = 11



G15 = 159

<sup>C(O)·G19</sup>  
 159

Patent location: claim 1  
 Note: substitution is restricted  
 Note: or oxides, pharmaceutically acceptable  
 salts, solvates, or prodrugs  
 Stereochemistry: 7 - R or S

L18 ANSWER 3 OF 6 MARPAT COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 141:33822 MARPAT  
 TITLE: The use of aryl- and heteroaryl-substituted  
 tetrahydroisoquinolines in the treatment of  
 chronic and neuropathic pain, migraine  
 headaches, and urge, stress and mixed urinary  
 incontinence  
 INVENTOR(S): Frail, Donald Edward; Arneric, Stephen Peter;  
 Wishka, Donn Gregory; Wong, Erik Ho Fong;  
 Beck, James Peter  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050630	A1	20040617	WO 2003-IB5504	20031124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,			


NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003283646 A1 20040623 AU 2003-283646 20031124  
US 2004248932 A1 20041209 US 2003-724856 20031201

PRIORITY APPLN. INFO.: US 2002-430285P 20021202  
WO 2003-IB5504 20031124

AB Methods are disclosed for using aryl- and heteroaryl-substituted tetrahydroisoquinolines for the treatment of chronic and neuropathic pain, the treatment and prevention of migraine headache, and the treatment of stress, urge and mixed urinary incontinence.

MSTR 1



G2 = Me  
G6 = F  
G10 = 41

<sub>41</sub><sup>G11-G12</sup>

G11 = 43

<sub>43</sub><sup>N—G13</sup>

G13 = 47

<sub>47</sub><sup>C(O)·G15</sup>

G15 = CH<sub>2</sub>Ph (opt. substd.)  
G20 = 68

<sub>68</sub><sup>G11-G12</sup>

G21 = 79

G11-G12  
79

Patent location: claim 1  
 Note: or pharmaceutically acceptable salts or  
 prodrugs  
 Stereochemistry: or isomers


REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE  
 IN THE RE FORMAT

L18 ANSWER 4 OF 6 MARPAT COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 141:33820 MARPAT  
 TITLE: The use of 4-phenyl-substituted  
 tetrahydroisoquinolines in the treatment of  
 pain, migraine headaches and urinary  
 incontinence  
 INVENTOR(S): Frail, Donald Edward; Arneric, Stephen Peter;  
 Wishka, Donn Gregory; Wong, Erik Ho Fong;  
 Beck, James Peter  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050628	A1	20040617	WO 2003-IB5339	20031120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505783	AA	20040617	CA 2003-2505783	20031120
AU 2003280137	A1	20040623	AU 2003-280137	20031120
EP 1572658	A1	20050914	EP 2003-772511	20031120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016919	A	20051018	BR 2003-16919	20031120
JP 2006509782	T2	20060323	JP 2004-556621	20031120
US 2004248933	A1	20041209	US 2003-724857	20031201
PRIORITY APPLN. INFO.:			US 2002-430242P	20021202
AB			WO 2003-IB5339	20031120
Methods are disclosed for using aryl- and heteroaryl-substituted tetrahydroisoquinolines, for the treatment of chronic and neuropathic pain, the treatment and prevention of migraine				

headache, and the treatment of stress, urge and mixed urinary incontinence.

MSTR 1




$\begin{array}{ll} G1 & = Me \\ G10 & = F \\ G16 & = CH_2Ph \text{ (opt. subst.)} \\ G26 & = 138 \end{array}$



$G29 = 160$

$\begin{array}{l} C(O)G16 \\ 160 \end{array}$

$G33 = 11$



Patent location: claim 1  
 Note: substitution is restricted  
 Note: or oxides, pharmaceutically acceptable salts, solvates or prodrugs

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 6 MARPAT COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 134:353258 MARPAT  
 TITLE: Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin  
 INVENTOR(S): Beck, James P.; Curry, Matt A.; Smith, Mark A.  
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA  
 SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032625	A1	20010510	WO 2000-US30329	20001103
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2389306	AA	20010510	CA 2000-2389306	20001103
BR 2000015320	A	20020709	BR 2000-15320	20001103
EP 1246806	A1	20021009	EP 2000-976885	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2003513074	T2	20030408	JP 2001-534777	20001103
AU 781179	B2	20050512	AU 2001-14597	20001103
US 2002143014	A1	20021003	US 2002-91949	20020306
US 6579885	B2	20030617		
US 2003203920	A1	20031030	US 2003-426097	20030429
US 2005020597	A1	20050127	US 2004-917801	20040813
PRIORITY APPLN. INFO.:			US 1999-163269P	19991103
			US 2000-704305	20001102
			WO 2000-US30329	20001103
			US 2002-91949	20020306
			US 2003-426097	20030429


GI




AB      Diarylmethyltetrahydroisoquinolines (4R)- or (4S)-I [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl; R3 = H, halogen, (un)substituted OH, S(O)nH, CN, CHO, CONH2, alkyl, alkenyl, alkynyl, cycloalkyl; R4 = (un)substituted aryl, heteroaryl; R5-R7 = H, halogen, CN, (un)substituted OH, NH2, S(O)nH, CHO, CONH2, alkyl, alkenyl, alkynyl, cycloalkyl; R8 = H, (un)substituted OH; n = 0-2] were prepared for use as blockers of the reuptake of norepinephrine, dopamine and serotonin (no data). Thus, 3-bromobenzaldehyde is stirred in the presence of

methylamine and reduced with sodium borohydride followed by addition of  $\alpha$ -chloroacetophenone and reduction of the amino ketone in situ with sodium borohydride to give 3-BrC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>N(Me)CH<sub>2</sub>CH(OH)Ph; cyclization of the benzyl alc. with sulfuric acid followed by coupling with phenylboronic acid gave I (R<sub>1</sub> = Me; R<sub>4</sub> = Ph; R<sub>2</sub> = R<sub>3</sub> = R<sub>5</sub> = R<sub>6</sub> = R<sub>7</sub> = H) as an oil. Such compds. are particularly useful in the treatment of a neurol. and psychiatric disorders which are created by or are dependent upon decreased availability of serotonin, norepinephrine or dopamine, such as attention deficit-hyperactivity disorder (ADHD), anxiety, depression, and addiction disorders.


## MSTR 1



$\begin{array}{ll} G1 & = Me \\ G5 & = F \\ G10 & = 86 \end{array}$



$G11 = 11$



$G15 = 159$

$\begin{array}{c} C(O) \cdot G19 \\ 159 \end{array}$


Patent location: claim 1  
 Note: substitution is restricted  
 Note: or oxides, pharmaceutically acceptable  
 salts, solvates, or prodrugs  
 Stereochemistry: 7 - R or S

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE  
 IN THE RE FORMAT

L18 ANSWER 6 OF 6 MARPAT COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 134:353257 MARPAT  
 TITLE: 4-Phenyltetrahydroisoquinolines and use  
 thereof to block reuptake of norepinephrine,  
 dopamine and serotonin  
 INVENTOR(S): Beck, James P.; Smith, Mark A.  
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA  
 SOURCE: PCT Int. Appl., 79 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032624	A1	20010510	WO 2000-US30328	20001103
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2389300	AA	20010510	CA 2000-2389300	20001103
BR 2000015307	A	20020709	BR 2000-15307	20001103
EP 1246805	A1	20021009	EP 2000-976884	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2004501860	T2	20040122	JP 2001-534776	20001103
NZ 519146	A	20040227	NZ 2000-519146	20001103
AU 784280	B2	20060302	AU 2001-14596	20001103
PRIORITY APPLN. INFO.:			US 1999-163270P	19991103
			WO 2000-US30328	20001103


GI




AB Tetrahydroisoquinolines I [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl; R3-R7 = H, halogen, (un)substituted OH, S(O)nH, S(O)nNH<sub>2</sub>, CN, acyl, CONH<sub>2</sub>, alkyl, alkenyl, alkynyl, cycloalkyl; R8 = H, halogen, (un)substituted OH] were prepared for use as inhibitors of the uptake of norepinephrine, dopamine and serotonin in the treatment of various neurol. and psychiatric

disorders, e.g. ADHD (no data). Thus, 3-MeC<sub>6</sub>H<sub>4</sub>CHO was reductively alkylated with HOCHPhCH<sub>2</sub>NHMe and cyclized with 98% H<sub>2</sub>SO<sub>4</sub> to give 2,7-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline.


## MSTR 1



$\begin{array}{ll} G1 & = \text{Me} \\ G5 & = \text{F} \\ G10 & = 86 \end{array}$



$G11 = 11$



$G15 = 159$

$\begin{array}{c} \text{C}(\text{O})\text{-G19} \\ 159 \end{array}$

Patent location: claim 1  
 Note: substitution is restricted  
 Note: or oxides, pharmaceutically acceptable  
 salts, solvates, or prodrugs  
 Stereochemistry: 7 - R or S

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE  
 FOR THIS RECORD. ALL CITATIONS AVAILABLE  
 IN THE RE FORMAT